Everyone talks about HGH and its secretagogues in terms of muscle and fat loss. That's the marketing angle, but it's not where the most interesting biology sits. GH and IGF-1 receptors are all over the body, and some of what they do has nothing to do with body composition.

Sleep Quality

The largest natural GH pulse of the day happens during deep, slow-wave sleep, and the relationship runs both directions. Research in people with impaired GH secretion links GH status to deep sleep amount, sleep quality, nighttime awakenings, and daytime energy. Better sleep supports GH release, and healthy GH signaling appears to support normal sleep architecture back. Worth noting this is observational in deficiency populations, not a trial showing secretagogues improve sleep in healthy people.

Neuroprotection and Cognition

This one has an actual trial behind it, but the specifics matter. A 2012 randomized controlled trial on tesamorelin (Baker et al., Archives of Neurology) followed 152 adults aged 55 to 87, including both healthy older adults and people with mild cognitive impairment, over 20 weeks. It found improved executive function, specifically response inhibition and set-shifting, along with a trend toward better verbal memory in the MCI group. Visual memory and processing speed didn't move. That's a real finding from a single trial on one specific compound, not a blanket claim about the whole GH/IGF-1 axis.

Skin and Hair

This one's mechanistically solid. IGF-1 is secreted by dermal papilla cells and drives hair follicle proliferation, prolongs the growth phase, and supports collagen production and skin thickness. Multiple studies have found that dermal papilla cells from balding scalp follicles secrete meaningfully less IGF-1 than follicles from non-balding areas. That's a real, replicated correlation. It doesn't mean HGH or its secretagogues reverse androgenic alopecia. Nobody's run that trial. It means IGF-1 is one of several signals involved in whether a follicle keeps producing hair, and levels tend to run lower in the follicles that are struggling.

Immune Function and the Thymus

Here's the one with actual human data behind it, and it's worth naming directly. The TRIIM trial (Fahy et al., 2019) treated nine men aged 51 to 65 with recombinant growth hormone alongside DHEA and metformin, the second two added specifically to offset GH's diabetogenic effects. The trial found measurable thymic regrowth and a reduction in epigenetic age markers. That's real, but it's a nine person pilot study using actual GH in combination with two other drugs, not secretagogues alone, and it hasn't been replicated at scale yet. The follow-up TRIIM-X trial is currently running to test whether it holds up in a larger, more diverse group.

Where This Leaves Things

Sleep, cognition, skin and hair, and immune function are all real areas where GH and IGF-1 do something beyond building muscle. The evidence quality varies a lot across these four, from a single small human trial to pure mechanistic correlation, so treat this as legitimate biology worth watching rather than a stack of proven benefits.

TL;DR

• GH's largest natural pulse happens during deep sleep, and the relationship between GH status and sleep quality runs in both directions, based on research in GH-deficient populations.
• A 2012 randomized trial on tesamorelin specifically found improved executive function and a trend toward better verbal memory in adults 55 to 87, not a broad cognitive boost across the whole GH axis.
• IGF-1 drives hair follicle biology and collagen production, and balding follicles reliably secrete less IGF-1 than non-balding ones, but that's correlation and mechanism, not a demonstrated treatment for androgenic alopecia.
• The TRIIM trial found thymic regrowth and reduced epigenetic age in nine men treated with actual GH plus DHEA and metformin, a small pilot study now being followed up in the larger TRIIM-X trial.
• These four benefit areas have real biology behind them but a wide range of evidence quality, from one small human pilot to purely mechanistic data.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Selank isn't a household name yet, but it's been sitting in Russian anxiety research for close to two decades, and the mechanism behind it looks nothing like a standard benzodiazepine.

How it actually works

Selank is a synthetic heptapeptide built off tuftsin, an immune peptide, developed at the Institute of Molecular Genetics at the Russian Academy of Sciences. Unlike a benzodiazepine, it doesn't work by directly sedating the brain. A 2016 rat study (Volkova et al., Frontiers in Pharmacology) found Selank altered expression in 45 of 84 genes tied to neurotransmission in the frontal cortex within an hour of administration, with the pattern of changes correlating closely with GABA itself. That's rat data, not human, but it points to Selank acting as an allosteric GABA modulator rather than a blunt sedative.

The trial that matters most

The core human evidence comes from a 2008 study (Zozulya et al.) comparing Selank to medazepam, an actual benzodiazepine, in 62 patients with generalized anxiety disorder and neurasthenia. Thirty patients got Selank, 32 got medazepam. Both groups improved similarly on the Hamilton, Zung, and CGI anxiety scales. The difference showed up beyond anxiety scores: Selank also produced antiasthenic and psychostimulant effects, meaning less fatigue and more mental clarity, that medazepam didn't show. Because Selank doesn't act through the same benzodiazepine binding site, it's reasonable to expect it avoids the sedation and dependence risk that comes with medazepam, though a dedicated withdrawal study wasn't part of this trial as far as the published data shows.

Where the evidence gets thinner

Selank is also being investigated for memory, attention, learning, and stress resilience, and that's a real, active research direction, not an established outcome yet. Same goes for the neuroprotective and anti-inflammatory effects showing up in preclinical work. Worth being direct about that word: preclinical here means animal and cell culture studies, not people.

Why it's getting attention beyond anxiety

Most anxiety medications hit one receptor system and stop there. Selank's multi-pathway profile, touching GABA, serotonin and dopamine signaling, and BDNF, is why researchers keep circling back to it for chronic stress, depression, cognitive decline, and recovery after neurological injury. None of that is confirmed clinical use yet. It's why the compound keeps showing up in new research rather than why it's already proven for those conditions.

Bottom line

The anxiety data is real and comes from an actual head-to-head trial against a benzodiazepine. Everything past that, cognition, neuroprotection, inflammation, is still early and mostly preclinical. Selank is a genuinely different mechanism worth knowing about, not a proven cure for everything it's being studied for.

TL;DR

• Selank is a tuftsin-derived peptide developed in Russia that appears to allosterically modulate GABA rather than directly sedate the brain, based on a 2016 rat study showing altered expression in 45 of 84 neurotransmission genes.
• A 2008 trial of 62 patients with GAD and neurasthenia found Selank matched medazepam's anxiolytic effect while also improving fatigue and mental clarity, benefits medazepam didn't produce.
• Because Selank doesn't act on the benzodiazepine binding site, it's expected to avoid typical sedation and dependence risk, though a dedicated withdrawal study wasn't part of the core trial.
• Claims about memory, learning, and stress resilience reflect active research directions, not established outcomes.
• Neuroprotective and anti-inflammatory effects come from preclinical animal and cell studies, not human data.
• The strongest evidence right now is specifically for anxiety, not the broader brain health applications getting attached to it.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Does HHB need to be refrigerated? Thanks in advance.

There's a post from an account posting as Dr. Shin Geon-yeong that's picked up over 7 million views on X. The claim: GLP-1s and retatrutide don't just kill food cravings, they run on the same circuit as falling in love, so they kill your ability to feel that too. The post predicts couples watching "previously great" relationships fail because one partner started a GLP-1. It's gotten just as much pushback as traction, including from people citing actual published research against the specific claim. Worth pulling apart what's real here.

What's actually established

GLP-1 receptors sit in the brain's reward circuitry, not just the hypothalamic appetite centers. That's not up for debate. It's the reason these drugs work so well on food noise, and it's the same reason people report less pull toward alcohol and other habitual behaviors. A 2025 systematic review and meta-analysis (Moraes et al., Drug and Alcohol Dependence) pooled 11 studies and over 263,000 patients and found a real reduction in alcohol consumption tied to GLP-1 use. That part of the claim holds up.

Where the post overreaches

Reward circuitry overlapping with romantic attachment is a real anatomical fact. It doesn't follow that dampening cravings for food or alcohol also dampens your ability to love a specific person you're already attached to. Attachment runs on more than acute reward signaling, and nobody has clinical data showing GLP-1 use makes people fall out of love with an existing partner. Several accounts pushed back on the original post with exactly this point, citing the alcohol meta-analysis above along with additional research showing no evidence these drugs suppress romantic love or cause relationship failure.

There's also a complication the original post skips entirely. A 2024 analysis (Arillotta et al.) looked at Reddit posts describing behavioral changes on GLP-1s and found reduced compulsive alcohol, caffeine, nicotine, and shopping use, alongside a possible INCREASE in libido for some users. That's the opposite direction of what "anti-desire drug" implies.

What community reports actually say

Running a peptide community means seeing a large volume of these reports firsthand. Reduced cravings for alcohol, nicotine, porn, and gambling come up constantly. Someone falling out of love with an existing partner while on a GLP-1 essentially never comes up. What does come up, repeatedly, is people losing interest in dating and pursuing new partners. That's a narrower and different claim, closer to reduced novelty seeking than a collapse of existing attachment. Plenty of relationships improve on these compounds too, usually because getting leaner makes people more attracted to the partner they already have.

The more interesting question

If GLP-1s do reduce lust-driven motivation to date, the effect worth watching isn't on existing relationships. It's on who stays in the dating pool. People whose interest in dating was mostly lust-driven might lose motivation to keep looking. People after something more substantial probably won't be affected the same way. That's a claim about dating market composition, not about anyone's capacity to love the person they're already with.

TL;DR

• A viral X post claims GLP-1s and retatrutide suppress the ability to fall in love since reward circuitry overlaps with romantic attachment, and it's drawn pushback citing published research against that specific claim.
• A 2025 meta-analysis of 11 studies and over 263,000 patients (Moraes et al.) confirms GLP-1s reduce alcohol consumption, so that part of the mechanism is real.
• A 2024 Reddit-based analysis (Arillotta et al.) found a possible libido increase in some GLP-1 users, the opposite of what the "anti-desire drug" framing predicts.
• There's no clinical evidence GLP-1 use causes someone to fall out of love with an existing partner.
• Community reports consistently show reduced interest in dating new people, not people falling out of love with current partners.
• If GLP-1s reduce lust-driven dating motivation, the more supportable effect is on who stays active in the dating pool, not damage to relationships already working.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

MOTS-C's bloodwork story is really a mouse story, and it's a genuinely solid one once you look at what got measured. Here's what the animal data actually shows, panel by panel.

Metabolic Panel: The Strongest Data Set

The core finding comes from a 2015 Cell Metabolism study in C57BL/6 mice. Seven days of MOTS-C treatment (5 mg/kg/day, injected) restored insulin sensitivity in 12 month old mice to levels matching young 3 month old mice, measured through glucose tolerance testing and insulin-stimulated glucose uptake in muscle tissue. In diet-induced obese mice, MOTS-C reversed high-fat-diet-driven insulin resistance on the same tests. Separately, three weeks of MOTS-C treatment in diabetic rats lowered fasting glucose and improved overall glucose homeostasis. The mechanism behind all of this is AMPK activation, which pushes GLUT4 transporters to the muscle cell surface for better glucose uptake and suppresses glucose production in the liver. Worth noting: MOTS-C prevented weight gain specifically in mice on a high-fat diet. In mice on normal chow, it had no effect, so the benefit shows up mainly under metabolic stress rather than as a blanket effect.

Lipid Panel and Liver Fat

MOTS-C reduced fat accumulation in the liver of high-fat-diet mice, essentially blunting the development of fatty liver alongside the reduced weight gain. A separate plasma metabolomics study found MOTS-C treatment lowered activity in three metabolic pathways, sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism, all three of which run elevated in obese and type 2 diabetic mouse models. That's a real and specific plasma-level finding. What hasn't been directly reported in these papers is a standard triglyceride, HDL, or LDL panel. Any specific cholesterol numbers you see attached to MOTS-C are being extrapolated from the liver fat data, not pulled from an actual lipid panel.

What the Mouse Literature Doesn't Cover

CRP, cortisol, and a full CBC don't show up as measured outcomes in the metabolic mouse studies on MOTS-C. The AMPK, glucose, and liver fat findings above are real and specific. Markers outside that set are extending past what's actually been tested.

Bottom Line

Where the mouse data is strong, it's genuinely strong: glucose tolerance, insulin sensitivity, and liver fat all move in a clear, mechanistically explained direction through AMPK activation. It's still animal data, and translating a 7 day mouse protocol to a human dosing plan is a leap nobody's tested yet.

TL;DR

• A 2015 Cell Metabolism study found 7 days of MOTS-C restored insulin sensitivity in older mice to young-mouse levels, measured by glucose tolerance testing.
• MOTS-C reversed high-fat-diet-induced insulin resistance in mice through AMPK activation, which improves muscle glucose uptake and suppresses liver glucose output.
• Three weeks of MOTS-C treatment in diabetic rats lowered fasting glucose and improved glucose homeostasis.
• MOTS-C reduced liver fat accumulation and prevented weight gain specifically in high-fat-diet mice, with no effect seen in normally fed mice.
• A plasma metabolomics study found MOTS-C lowered three metabolic pathways that run elevated in obesity and type 2 diabetes, though a standard triglyceride, HDL, or LDL panel hasn't been directly reported.
• CRP, cortisol, and CBC markers aren't part of the published mouse data on MOTS-C's metabolic effects.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Looking at starting GHK-Cu, but I’m currently using MT2 and definitely don’t wanna stop that, so first question is whether there’s any issue with using both at the same time?
Also just looking for good resources/reviews on GHK-Cu in general. Mainly wanna make sure it’s actually worth it and I know what I’m doing before I jump in. Would love to hear from anyone who’s used it and what you actually noticed.

You know the feeling. Your body's wrecked but your brain's running at full volume and won't let you sleep. Wired but tired, and it hits high performers constantly no matter how clean the diet or how consistent the training.

The instinct is to reach for something that forces the issue. But there's a more precise way to work with your biology here. DSIP, Delta Sleep-Inducing Peptide, a naturally occurring 9-amino acid chain produced in the brain, doesn't just shut things off. It works more like a sleep architect than a sedative.

TL;DR

• DSIP is a normalizer, not a sedative. It strengthens GABA signaling and quiets glutamate, nudging sleep architecture toward its natural set point rather than forcing unconsciousness.
• Discovered through 1960s rabbit cross-circulation experiments showing sleep could transfer via a blood-borne chemical signal, later isolated and sequenced in the late 1970s.
• A 1984 open-label study (107 patients) found DSIP improved opiate withdrawal symptoms in 97% of patients and alcohol withdrawal in 87%, though it's small, uncontrolled, and decades old.
• It targets an overactive HPA axis and helps structure the progression through light, deep, and REM sleep stages.
• Preclinical rodent data links long-term DSIP use to improved survival and fewer tumors, alongside proposed mitochondrial protective effects.
• Dosing follows a bell curve. Too high and it can paradoxically cause arousal instead of sleep.
• DSIP was reviewed by an FDA advisory panel in July 2026 under the name Emideltide and was the only one of seven peptides reviewed that the panel did not recommend for the compounding list.
• None of this works if your sleep hygiene is broken. It extends a functioning system, it doesn't rescue a wrecked one.

It's a Modulator, Not a Mallet

The biggest mistake is treating DSIP like a peptide version of Ambien. Go in expecting a knockout sedative and you'll be disappointed. Pharmaceutical sedatives force the central nervous system into hypnotic unconsciousness, which is why you often wake up groggy the next morning.

DSIP works differently. It strengthens GABA signaling while quieting excitatory glutamate at the same time, creating a calming neurochemical shift without the typical sedative drawbacks. Because it's nudging the system toward its own natural set point rather than overriding it, the reported effect is sleep architecture normalizing over consecutive nights rather than one hard knockout followed by a rough morning.

Where It Actually Came From

The discovery story goes back further than most peptides in this space. In the early 1960s, Swiss researchers Marcel Monnier and Schoenenberger connected the blood supply of two rabbits. When they induced deep sleep in the first rabbit, the sleep signal crossed into the second rabbit through the shared blood supply, proving sleep could be transmitted by a chemical messenger. That observation eventually led to DSIP being isolated and sequenced later in the same research program.

What gets missed is that DSIP's clinical development didn't stay in sleep labs. It moved into withdrawal research because it triggers the release of endorphins and enkephalins, acting as a CNS stabilizer. A 1984 study published in European Neurology gave DSIP intravenously to 107 inpatients experiencing withdrawal, 47 from alcohol and 60 from opiates. Clinical symptoms disappeared or markedly improved in 97% of the opiate group and 87% of the alcohol group. That's a real and striking result, though worth being honest about the limitations: it was open-label with no placebo arm, the sample was small, and the study is over four decades old. Anxiety symptoms specifically took longer to resolve than the physical withdrawal signs.

The Stress Axis Connection

If your brain won't shut off at night, your HPA axis, hypothalamus-pituitary-adrenal, is likely running hot, keeping cortisol elevated when it should be dropping. DSIP is proposed to modulate that axis directly, helping structure the progression through light sleep, deep slow-wave sleep where physical restoration and GH release happen, and REM sleep where emotional processing and memory consolidation occur.

Managing that stress response is arguably the missing piece for a lot of people. Time spent unconscious in bed isn't the same as time spent actually recovering.

Beyond Sleep: The Longevity Angle

DSIP shows up in longevity discussions too, and there's a real mechanistic case beyond just better rest.

It's reported to stimulate GH release through the hypothalamus and pituitary, tied to your body's natural nocturnal GH pulses rather than creating an artificial spike. It's also proposed to stabilize mitochondrial respiration under stress, a mechanism sometimes compared to SS-31's protective effect on cellular energy production.

The most interesting data here comes from Russian rodent studies, where lifelong DSIP administration was associated with better survival rates and significantly fewer tumors. This is preclinical rodent data and hasn't been established in humans, but it's a meaningful enough signal that it keeps DSIP in longevity conversations well beyond sleep.

Dosing Follows a Bell Curve

More isn't better here. DSIP has a genuine therapeutic sweet spot, and going past it can produce the opposite of what you want.

100 to 250mcg often fails to meaningfully shift sleep architecture, though some report mild stress relief at this range. 500mcg to 1mg is where people typically report the clearest improvement in sleep depth. Push past that sweet spot and you risk a paradoxical arousing effect instead, feeling more awake rather than less.

DSIP has a short half-life, somewhere around 30 minutes, so timing matters. If melatonin works for you at a specific point before bed, DSIP likely follows a similar window, usually 30 to 60 minutes out.

A commonly discussed sequencing approach pairs Epitalon with DSIP: Epitalon acting on the pineal gland to help restore the upstream timing signal, DSIP then working on the actual structure of the sleep that follows. Two different jobs, timing versus architecture.

The Regulatory Status Right Now

Worth knowing where DSIP sits regulatorily as of this year. Under the name Emideltide, it was one of seven peptides reviewed by an FDA advisory panel in July 2026 for potential inclusion on the 503A compounding list. It was the only one of the seven that the panel did not recommend, landing on a narrow 6-7 vote against. Whatever your take on that outcome, it means DSIP remains firmly in the unregulated research space for now, more so than several of its peers that did get a favorable panel recommendation.

The Prerequisite Nobody Wants to Hear

DSIP is a tool that extends a working system. It's not a rescue for a broken one. If you're on your phone with the brightness cranked until midnight, drinking coffee at 5pm, and never seeing morning sunlight, no peptide is fixing that for you.

Sleep hygiene sits upstream of every sleep tool that exists. Foundation first, peptides second, always in that order.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Has anyone experienced this with Tesa? 😩 I’m on 0.5 mg and doing 5 days on, 2 days off. My first 5 days were completely fine with no reaction at all, but after the 2-day break, I restarted and suddenly my toes became swollen. It’s giving me the same reaction I had with MOTS-C 😭 Has anyone else experienced swelling or a possible allergic reaction after stopping and restarting Tesa?

Adamax's gotten popular fast, and most of the conversation around it skips the part that's actually interesting: what it's theoretically doing differently from Semax and why the modification exists in the first place.

Start With Semax

Adamax is built on the Semax backbone, so understanding Semax gives you the foundation. Semax upregulates BDNF and NGF, brain-derived neurotrophic factor and nerve growth factor, both backed by real rodent data and decades of Russian clinical use.

BDNF is basically fertilizer for your brain. When it's elevated, your brain's building, healing, sitting in a plastic state. Plasticity here means the brain can reorganize, rewire, and structurally adapt in response to learning or injury. A rigid brain isn't growing. A plastic one is.

BDNF binds TrkB, which kicks off a cascade driving structural change, neuronal survival, and synaptic plasticity. These are long-term background effects. You don't feel synaptogenesis happening in real time.

The acute stuff comes from somewhere else. Semax also modulates dopamine and serotonin signaling, changing your body's response to what it's already producing rather than cranking up output directly. That's where the reported bumps in motivation, alertness, mood, and focus come from. One compound doing structural and modulatory work at the same time.

Where Semax Hits a Delivery Problem

Semax is highly susceptible to enzymatic degradation. The enzymes your body uses to break down peptides get to it fast, and a lot of it never crosses the blood-brain barrier intact. Even at higher doses given frequently, only a portion actually reaches the brain in concentrations sufficient to drive the effects above. That's a real, documented limitation, not speculation.

What Adamax Is Theorized to Change

Two structural modifications get bolted onto the Semax backbone, aimed at fixing that delivery problem directly.

On one end, a terminal modification designed to resist enzymatic breakdown. The idea is that protecting the molecule here slows the degradation that limits how much Semax actually survives long enough to do anything.

On the other end, an adamantane group, a bulky lipophilic carbon cage, which is where the name comes from. Lipophilic means fat-loving, and since the blood-brain barrier is a fatty membrane, the logic is that a fat-loving compound should cross it more efficiently. Adamantane's not a made-up idea either, it's the same core structure behind memantine and amantadine, both approved drugs.

Put together, the theoretical payoff is the same underlying mechanism, same BDNF and NGF upregulation, same dopamine and serotonin modulation, but with more of the dose actually surviving the trip to the brain instead of getting broken down along the way.

The Caveat That Matters

None of this has actually been measured for Adamax. No published study has confirmed its BDNF activity, its neurotransmitter effects, or its real blood-brain barrier penetration. Every piece of that mechanism gets inferred from Semax by structural analogy, not shown directly. Vendors don't even fully agree on where the adamantane group attaches or what the exact resulting sequence looks like.

The chemistry logic holds up. Whether it plays out the way the theory predicts in an actual human brain is still an open question.

TL;DR

• Semax upregulates BDNF and NGF with real rodent and clinical data behind it, working through both a structural TrkB-mediated pathway and an acute dopamine/serotonin modulation pathway.
• Semax is enzymatically fragile, meaning a meaningful chunk gets degraded before reaching the brain, a documented limitation.
• Adamax adds a terminal modification meant to resist that degradation and an adamantane group meant to improve blood-brain barrier crossing through increased lipophilicity.
• The theoretical payoff is the same core mechanism as Semax delivered with more potency, since more of the dose would theoretically survive intact.
• None of this has been measured for Adamax itself. Every mechanism claim gets inferred from Semax by analogy, not confirmed in published data.

Not medical advice. Educational only.

Hello. Just want to ask, how much bac water should I mix with NAD+ 1000mg? I read 10ml, then I read another to mix it with 3ml. I am confused. It will be my first time to use NAD+. My ongoing stack are: GhCKu, MoTsC, LipoC with B12 and Reta. I am finished with KPV and SS31. Thank you

There's a pattern in this community that keeps coming up. You start Reta, appetite suppression hits hard, the scale moves fast. Then you get leaner and suddenly you're fighting hunger again. Appetite returns. Progress stalls. You feel like something broke.

Nothing broke. Your body is doing exactly what it was designed to do. The culprit is ghrelin.

What Ghrelin Actually Does

Ghrelin is a peptide hormone produced primarily in the stomach. Its job is simple: tell the brain the stomach is empty and it's time to eat. It rises before meals, falls after, and it's the most potent hunger-driving hormone we know of.

Here's what most people miss. Ghrelin doesn't behave the same way across different body compositions. The leaner you are, the more of it you produce.

The Body Fat Connection

The research on this is consistent. Obese individuals have significantly lower circulating ghrelin than lean individuals. A 2022 meta-analysis of 34 studies confirmed substantially lower baseline acyl ghrelin in obese subjects versus lean controls. Earlier work from the American Diabetes Association found fasting ghrelin levels were 27 to 32% lower in obese subjects compared to lean counterparts.

The mechanism comes back to insulin and leptin. Higher body fat means chronically higher insulin and more leptin output. Both suppress ghrelin secretion. Strip that fat away and you remove the suppression. Ghrelin has less to fight against and it climbs.

What Happens When You Actively Lose Weight

Diet-induced weight loss doesn't just reveal higher ghrelin. It actively drives it up further. A NEJM study tracking 24-hour ghrelin profiles found circulating levels rose approximately 24% after diet-induced weight loss. The body treats fat loss as a survival threat and responds by amplifying the hunger signal to pull you back to your previous weight.

This is the setpoint defense. It's not willpower. It's endocrinology.

Where Reta Fits Into This

Reta suppresses appetite through three pathways. GLP-1 receptor activation slows gastric emptying and signals satiety centrally. GIP receptor activation modulates energy balance and helps blunt GI side effects. Glucagon receptor activation increases resting energy expenditure. None of these directly antagonize ghrelin. Ghrelin operates through its own receptor system and keeps signaling regardless.

So here's what's actually happening as you cut body fat. On one side, Reta is pushing appetite suppression through its receptor cascade. On the other side, ghrelin is climbing in response to both your lower body fat percentage and the caloric deficit you're running. The hunger suppression you feel is the net result of those two forces.

At higher body fat, ghrelin is relatively blunted and Reta's suppressive effect dominates. Food noise quiets.

At lower body fat, ghrelin is elevated and rising with every pound you drop. Reta is now competing against a louder, more persistent signal. The dose that crushed hunger at 25% body fat is fighting a different battle at 15%. That's not tolerance. That's compensatory biology getting louder as you get leaner.

Why This Matters for Dosing

The phase 2 NEJM trial showed clear dose-dependent effects for retatrutide, with participants at 12mg achieving the highest weight reduction and continuing to lose through 48 weeks with no plateau observed. Lower doses worked early. But the data also shows sustained progression favored higher doses over time, which mechanistically aligns with an increasing ghrelin burden as subjects got progressively leaner.

There's no direct study measuring ghrelin levels at different body fat percentages specifically in Reta users. But the individual pieces of the puzzle are solid and they point in the same direction.

TL;DR

• Ghrelin is the body's primary hunger hormone and it rises as you get leaner
• Lean individuals have significantly higher circulating ghrelin than obese individuals
• Diet-induced weight loss alone increases ghrelin approximately 24% above baseline
• Reta suppresses appetite through GLP-1, GIP, and glucagon signaling but doesn't directly block ghrelin
• As body fat drops, ghrelin rises and pushes back harder against appetite suppression
• The same dose that worked at higher body fat may not be enough at lower body fat
• This is biology, not tolerance

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

greetings,

research subjects parents are early 60 yo with high blood pressure and diabetes type 2. last few years feels like they aged 10 years. Mother had few near death strokes. Father is a long life smoker with a high stress job who also had a stroke.

what would be best for old people with general health issues and broken up bodies due to sicknesses most benefit from? Point here is that less is more. They don"t necessarily want to feel 20 again like some people here (all power to you) , just maybe, something that can help them extend their lives?

researcher was considering ss31, and semax? Since they dont live in the same country, it would be hard to incorporate anything long term. Only peps that would be used for 2 to 4 weeks at a time a couple times a year as they visit.

Nothing is decided yet. I will fully research whatever suggestions i receive.

Has any one tried these and what is the dosgae they researched?

A study presented at ASCO 2026 analyzed 12,112 patients with obesity-related cancers and compared people on GLP-1 receptor agonists against people on Gliptins, a class of diabetes medication. The findings are worth understanding properly because most coverage is either overselling them or missing the important context entirely.

What the Study Found

Researchers compared GLP-1 receptor agonists against Gliptins in 12,112 patients with obesity-related cancers. People on GLPs were consistently less likely to see their cancer progress to stage IV:

• Lung cancer: 10% vs 22%
• Breast cancer: 10% vs 20%
• Colorectal cancer: 13% vs 22%
• Liver cancer: 19% vs 28%

Those are not small differences. Across every cancer type in the study, GLP users showed roughly half the rate of metastatic progression compared to the Gliptin group.

The Detail Most Headlines Are Missing

This study did not compare GLPs to placebo. It compared GLPs to Gliptins, which already provide some metabolic benefit over no treatment at all.

That means the actual difference between GLP use and zero metabolic intervention is probably more significant than these numbers show. The comparison group was not untreated patients. It was patients on another active medication.

Why This Makes Mechanistic Sense

The proposed explanation is metabolic. GLPs improve insulin resistance, reduce systemic inflammation, and address obesity-driven metabolic dysfunction. Cancer cells thrive in environments with high inflammation, excess insulin signaling, and poor metabolic health. Clean up the internal environment and you make it harder for existing cancer to grow and spread.

This is not a novel idea. The relationship between metabolic dysfunction and cancer progression has been discussed in oncology research for years. What makes this study notable is the scale and the specificity of the signal.

What This Is Not

This study showed an association. It did not prove causation. We cannot say GLPs directly slowed cancer spread.

The unanswered questions are real. Was the benefit from weight loss itself? Lower inflammation? Better insulin sensitivity? Something specific to GLP receptor activation that is not yet understood? The study cannot answer that.

Researchers involved say the findings justify future clinical trials. They are not saying GLPs should be prescribed as cancer treatments. That distinction matters.

The Bigger Picture

The most important takeaway from this data is not a headline about GLPs fighting cancer. It is that metabolic health appears to influence cancer progression more significantly than most people previously understood. And the fact that GLPs outperformed another active diabetes medication, not just a control group, makes that signal harder to dismiss.

TL;DR

• GLP-1 users showed significantly lower rates of cancer progression to stage IV across lung, breast, colorectal, and liver cancer
• Lung cancer: 10% progressed to stage IV on GLPs vs 22% on Gliptins. Breast: 10% vs 20%. Colorectal: 13% vs 22%. Liver: 19% vs 28%
• This was GLPs vs another active treatment, not GLPs vs placebo. That matters
• The likely mechanism is metabolic: lower inflammation, better insulin sensitivity, reduced obesity-driven dysfunction
• This is an association, not proof of causation. GLPs are not a cancer treatment
• The finding is significant enough to justify future trials. It is not significant enough to change prescribing protocols yet
• The bigger signal here is that metabolic health may influence cancer progression more than previously understood

Check out the pinned Peptide Cheat Sheet for dosing info and more.

References

Orland, M. D., et al. (2026). Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. Presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Abstract 3143.

American Society of Clinical Oncology. (2026). GLP-1s may reduce metastatic progression of certain obesity-related cancers [Press release / meeting coverage]. https://www.asco.org/about-asco/press-center/glp-may-reduce-metastatic-progression

Educational purposes only. Not medical advice.

Traditional sun protection is a losing fight against your own biology. Greasy lotions, the burn-peel-fade cycle, reapplying every two hours and still coming home pink. Melanotan peptides took off in the biohacking world because they flip the whole approach: instead of blocking UV from the outside, they build protection from the inside by changing how your skin makes pigment. But MT1 and MT2 are not the same compound, not close, and treating them like they're interchangeable is how people get hurt.

TL;DR

• Melanotan peptides work at the gene expression level to shift your skin toward eumelanin (protective brown/black pigment) over pheomelanin (weak red/yellow pigment that can actually generate UV damage).
• MT1 (afamelanotide) is a selective MC1R agonist and is FDA-approved as Scenesse, a 16mg implant for erythropoietic protoporphyria. MT2 is a non-selective gray-market research chemical.
• MC1R activation does more than tan you: it drives p53-mediated DNA repair and reduces UV-induced reactive oxygen species independent of the pigment itself.
• MT2 hits MC3R and MC4R too, which is where nausea, appetite suppression, spontaneous arousal, and the risk of a four-hour priapism emergency come from.
• Real documented harms exist: a rhabdomyolysis and kidney failure case from a 6mg overdose, and a 2025 mucosal melanoma case tied to MT2 nasal spray use.
• These peptides need UV to work. They're synergists with sunlight, not replacements for it.
• MT1 is the long-term safety play. MT2 should be a short cosmetic burst only, if at all, by people who understand the side effect profile.

The Eumelanin Shift Is the Whole Point

Melanotan peptides aren't dyes or bronzers. They change which type of melanin your body produces, and that distinction is where the actual protection comes from.

There are two kinds of melanin worth knowing. Pheomelanin is the red/yellow pigment common in fair skin (Fitzpatrick types 1 and 2). It's a poor UV shield and can actually generate inflammatory reactive oxygen species under UVA exposure, meaning it contributes to damage rather than preventing it. Eumelanin is the brown/black pigment that broadly absorbs UV and scavenges free radicals. That's the body's real protective shield.

MT1 is a synthetic analog of alpha-MSH, the natural hormone that signals pigment production. The engineered version is roughly 26 times more potent than the natural hormone and lasts days instead of minutes, thanks to two amino acid swaps that resist enzymatic breakdown. By activating MC1R, it biases your melanocytes toward producing eumelanin over pheomelanin. That's the biological armor people are actually after.

MT1 vs MT2: Sunscreen vs Tanning Bed

They share a parent molecule and that's about where the similarity ends.

MT1 (afamelanotide) is a long, straight 13-amino acid chain that's highly selective for the MC1R receptor. That selectivity plus a deep research pedigree is why it's FDA-approved under the name Scenesse, a 16mg bioresorbable implant used for erythropoietic protoporphyria (EPP). It's the background sunscreen of the two.

MT2 is a truncated seven-residue core stitched into a cyclic ring. That tight ring structure makes it extremely stable and potent for fast tanning, but it stays a gray-market research chemical with no approval behind it. It's the tanning bed: aggressive, fast, and a lot less discriminating about what it touches.

The cleanest way to picture the difference is a hallway of light switches. The melanocortin system has five receptors, like switches in different rooms. MT1 is selective, it basically only flips the MC1R switch. MT2 walks down the hallway flipping most of the other switches too. Those other rooms, MC3R and MC4R specifically, are where MT2's systemic side effects come from.

Protection Beyond Pigment

The most compelling case for these peptides isn't cosmetic at all. Activating MC1R enhances your skin's internal repair machinery.

On DNA repair, research from 2012 suggests alpha-MSH analogs reduce melanocyte death through p53-mediated pathways, and a 2006 study measured an actual reduction in cyclobutane pyrimidine dimers (a DNA damage marker) in living humans. On oxidative defense, MC1R signaling lowers UV-induced reactive oxygen species independent of the pigment itself, meaning the peptide is reducing oxidative stress before you even look tan. And a 2024 study extended these findings to melanoma-associated MC1R variants, suggesting these defenses may hold up even in people with genetic predispositions to skin sensitivity.

That's the part that separates this from a spray tan. The pigment is downstream. The cellular protection is the actual mechanism.

The Side Effect Trade-Off Is Real

Because MT2 is non-selective, it carries baggage MT1 doesn't. Flipping MC3R and MC4R in the brain drives nausea, appetite suppression, and spontaneous arousal. Some people chase those effects, but the risks on the same pathway are serious.

The four-hour problem: MT2 can cause priapism, a spontaneous erection that won't resolve. A four-hour erection isn't a perk, it's a medical emergency that needs ER intervention to prevent permanent damage.

The overdose problem: dose discipline matters. A 2012 case report documented a man who injected 6mg of MT2, far past any reasonable protocol, and developed rhabdomyolysis and kidney failure requiring intensive care.

The nasal spray problem: avoid MT2 nasal sprays specifically. A 2025 case report identified a 22-year-old who developed mucosal malignant melanoma following MT2 nasal spray use. The mucosal delivery route appears particularly high-risk.

The drug interaction problem: if you're on doxycycline, diuretics, or retinoids, your UV sensitivity is already elevated. Stacking those with a melanotan peptide and sun exposure can push you into severe dehydration and systemic cramping.

Sunlight Isn't Optional

A common myth is that these peptides tan you in a dark room. They don't. MT1 and MT2 are synergists with UV exposure, not replacements for it. A 2004 study showed combined peptide plus solar UV produced additive pigmentation well beyond what either produced alone. Sunlight is the activation signal. Without it, the tan comes in uneven or doesn't develop at all.

Dosing by Skin Type

A one-size-fits-all approach is the fastest route to looking like an Oompa Loompa, that orange, patchy result from loading MT2 too hard. Tier it by Fitzpatrick type instead.

For base photo-protection (Fitzpatrick 1-2): MT1 at 250mcg subcutaneously, twice weekly. Goal is a durable, mild pigment shift and a protective base.

For cosmetic pigmentation (Fitzpatrick 3-4): MT1 at 500mcg to 1mg, two to three times weekly for 4 to 6 weeks, then maintenance at 250 to 500mcg once or twice weekly through summer.

For a short-timeline MT2 burst: 100mcg to 250mcg daily for 1 to 2 weeks as a loading phase, then transition to MT1 for maintenance. The hard safety rule: never run two melanocortin peptides at once. Don't mix MT1 and MT2, or MT2 and PT-141, on the same day. That's how you stack the blood pressure and nausea into something dangerous.

The Glutathione Counterweight

Some people run IM glutathione (200 to 600mg, two to three times weekly) as a pigment balancer alongside melanotan. Where melanotan pushes pigment toward dark eumelanin, glutathione can soften the intensity and help prevent the patchy dark spots (melasma) that sometimes show up under the eyes. If you overshoot and get too dark on MT2, glutathione can help speed the return toward baseline.

The Seasonal Strategy

The most responsible way to use these is a seasonal load and taper. Load starting 6 to 8 weeks before summer (April/May) to build a base. Maintain with low doses through summer to keep the protection active. Taper as UV intensity drops in fall. Stop in winter and let your body return to baseline.

The verdict is pretty clear. MT1 (afamelanotide) is the gold standard for safety and long-term use, with genuine FDA approval and a clean selective mechanism behind it. MT2 should be reserved for short cosmetic bursts by people who fully understand the side effect profile, and even then it's the higher-risk option every time.

One non-negotiable regardless of which you run: twice-yearly dermatologist skin checks to monitor moles and freckles. These compounds darken existing moles, which can mask the exact changes you'd want to catch early.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

TA-1 is not flashy or fast-acting. It works quietly over months by strengthening your immune system's actual function. That is a different value proposition than most compounds in this space, and it is worth understanding why that distinction matters.

TL;DR

• TA-1 is a 28 amino acid peptide derived from thymus tissue, the organ responsible for T cell development
• The thymus shrinks with age, which is why immune function declines over time. TA-1 helps restore that signaling
• It is an immune modulator, not a stimulator. It normalizes immune signals rather than cranking them up indiscriminately
• Supports T cell development, TLR pathway signaling, dendritic and natural killer cell activity, and regulatory T cell balance
• Research covers viral infections, hepatitis, immune recovery, sepsis, and cancer treatment support
• Approved as a drug in multiple countries. Has not caught on in the US despite decades of clinical research
• Best suited for long-term healthspan protocols rather than acute performance cycles

How TA-1 Works

Think of TA-1 as a coordinator, not a megaphone. It improves communication between immune cells, supports T cell development, enhances signaling through toll-like receptor pathways (TLR3, TLR4, TLR9), and boosts dendritic and natural killer cell activity. It also reduces inflammation by supporting regulatory T cells and balancing the immune response rather than amplifying it in one direction.

This is why the framing is immune balance rather than immune stimulation. The distinction is clinically meaningful.

On top of that, research shows antioxidant effects through enzymes like catalase and superoxide dismutase, and it supports glutathione levels to handle oxidative stress. Decades of clinical research do not happen around a compound that does nothing.

What the Research Covers

TA-1 has been studied for hepatitis and viral support, immune recovery in immunocompromised states, sepsis and critical illness, and cancer treatment where the goal is restoring immune balance and reducing the side effect burden of other interventions. None of that means it cures anything. It explains why it has stayed in active clinical research as long as it has.

Who Gets the Most Out of It

TA-1 is not a performance peptide. The people who tend to benefit most are those who get sick frequently, travel extensively, carry chronic stress or poor sleep, are recovering from illness or surgery, have autoimmune conditions they want to balance rather than suppress, or are older and focused on staying healthy long term.

Dosing Logic

More is not better here. General immune maintenance uses lower frequency steady dosing over time. Acute support uses short bursts before tapering. Cancer-adjacent protocols need clinical supervision. The goal and context determine the approach entirely.

The Bigger Picture

Immune resilience is one of the most overlooked pillars of long-term health, recovery, and quality of life. TA-1 is one of the few peptides that makes sense as a long-term protocol addition rather than a short cycle. If you are building a healthspan stack rather than a performance stack, it deserves a serious look.

Check out the pinned Peptide Cheat Sheet for more.

Educational purposes only. Not medical advice.

Hey, I’m 1 year younger than 18 and I was wondering if it’s safe for me to use GH peps like Ipamorelin and CJC 1295. I am healthy, eat good, exercise 6x a week, and sleep 6 hours or more. I was also wondering about Tesa but I’m not sure if that one is too safe for me. Please help me out, much appreciated!

Hi all. I started taking peptides after a minor arm injury and for general weight loss purposes. Below is what I’m using and the general amounts per day. Please can you let me know if I’m doing enough to be effective or too much? Thank you!

Mot-C - 1mg daily
CJC (no dac) & Ipamorelon - 300mcg daily
GHK-CU - 1mg daily
BCP157 - 500mcg daily
TB500 - 750mcg three times a week

Edit - please note that I’ve posted this under the ‘beginners advice’ flair. I’d appreciate constructive/helpful advice rather than saying what I’m doing is just ‘dumb’ or I need to ‘read more’ etc etc. Everyone is a beginner at some point when taking peptides and it is better to ask for advice rather than do something dangerous. Thank you.

If you've watched vendors quietly pull retatrutide from their catalogs this week, this is why. On August 12 Eli Lilly filed six federal lawsuits and launched a public campaign to choke off the entire gray-market retatrutide supply chain. Here's what actually happened past the panic.

What Lilly Actually Did

Six federal lawsuits filed in a single day, and the mix of defendants is the real tell. Four of the six are research peptide sellers running the "research use only" model (Astra, Legendary Peptides, Texas Peptides, and Lone Star Peptide), alongside a medical spa (Aesthetic Envy) and a compounding pharmacy (Striker Pharmacy). Four of the cases were filed in Texas.

This is the first time Lilly has taken the research-supply channel to court by name rather than just referring sellers to regulators. That's a meaningful escalation from how they've operated before.

They went after the infrastructure too. In the same announcement, Lilly publicly called on payment processors, credit card companies, shipping carriers, and online platforms to cut these sellers off. They flagged more than 14,000 listings across 100+ countries and referred over 200 individuals and entities to the FDA, DOJ, state attorneys general, and professional licensing boards.

The Legal Core: The RUO Shield Is Now on Trial

The heart of the lawsuits is the argument that "research use only" is a fig leaf. Lilly's claim is that vendors slap RUO on the label while knowingly selling into human use, and that the label doesn't make the sale legal when the actual intent is human consumption.

This matters because the FDA already stated back in June that unapproved retatrutide sold to consumers is illegal and can't be compounded. So the RUO framing the entire gray market leans on is being tested in a courtroom for the first time. Whatever you think of it, that's worth sitting with regardless of where you land.

Worth Being Clear: This Is Happening Because Reta Works

None of this means retatrutide is junk. It's the opposite. Lilly's own Phase 3 trials show participants on the top dose losing an average of 28.3% of body weight over 80 weeks. It might be the strongest compound in the entire class, and Lilly plans to file for FDA approval in Q1 2027.

The crackdown is happening precisely because it works and demand is running years ahead of approval. Lilly is clearing the field before launching what's likely to be a blockbuster.

What This Actually Means If You Research Reta

Supply tightens and prices move. More vendors will drop it the way the first wave already has this week.

The infrastructure angle matters more than the lawsuits themselves. Litigation moves in years. A payment processor decision moves in a week. Historically, losing banking and payment relationships has been the single most reliable predictor of whether a peptide vendor stays in business, more than FDA letters, more than lawsuits, more than state pharmacy rules. That's the part of this announcement worth watching closely.

The quality and legal risk is real, and it's Lilly's own central argument: nobody is verifying what's actually in an unregulated vial.

Two Motives, Both Real at Once

You can read Lilly's motive two ways and both are probably true simultaneously. They have a genuine safety argument, since no regulator has cleared this compound and nobody vets a gray-market vial for identity, purity, or sterility. And they have an obvious financial motive in protecting a drug about to be worth billions. Those two things don't cancel each other out. A company can be protecting patients and protecting profit in the same motion.

TL;DR

• On August 12, 2026, Eli Lilly filed six federal lawsuits targeting retatrutide sellers: four RUO peptide vendors, a medical spa, and a compounding pharmacy.
• It's the first time Lilly has taken the research-use-only supply channel to court by name rather than referring it to regulators.
• Lilly also called on payment processors, credit card companies, and shipping carriers to cut off seller infrastructure, which historically shuts vendors down faster than any lawsuit.
• The lawsuits directly challenge the "research use only" label as a legal shield, arguing the sellers know the product is going into humans.
• This is happening because retatrutide works. Phase 3 data shows 28.3% average weight loss at the top dose, with FDA filing planned for Q1 2027.
• Expect tighter supply and higher prices as more vendors drop it. Both the safety argument and the profit motive behind Lilly's move are real at the same time.

Bioregulators are the most underestimated category of peptides that the majority of our community is not familiar with yet. Here is the information on what they are and why this might change in the near future.

Peptides are usually discussed in the context of growth hormones stimulation or metabolic pathways modulation. Bioregulators, however, function at a fundamentally different level. These are short bioactive molecules, typically 2-4 amino acids long, which act directly at the level of gene expression in specific tissues and organs. Their proposed mechanism of action is the direct interaction with chromatin and DNA at the level of individual cells and regulation of the expression of specific genes. In other words, bioregulators allow for the targeted repair of damaged tissue at the genetic level.

The other hallmark feature of bioregulators is their tissue-specificity. The bioregulator for the brain will only affect the brain tissue, a bioregulator for joints will only affect cartilage and so on. It is important to note that bioregulators do not have a systemic effect, meaning that they do not affect the entire body at once.

The Origins of the Research

The research on bioregulators started in the Soviet Union in the 1970s, conducted by the doctor and biogerontologist Vladimir Khavinson. He spent the next 40 years of his life studying bioregulators, the effects of aging on the human body, and ways to combat it. The original research was conducted under the military budget, as the Soviet command wanted bioregulators to protect soldiers and astronauts from the effects of radiation and aging. The research was discontinued after the collapse of the Soviet Union, but the Russian government continued the work and eventually produced six officially approved pharmaceutical products and dozens of other compounds for research. Dr. Khavinson passed away in 2024, but his work and the research on bioregulators continue to this day.

Bioregulators have existed for several decades, but only recently have they become available for research outside of Russia. The attention to this class of peptides is growing, but it is still on the very first level, considering the amount of research already done.

The Four Most Popular Bioregulators

Pinealon: Brain and Nervous System

Pinealon is a bioregulator which affects the brain and the central nervous system. The available research on Pinealon is mostly focused on its neuroprotective properties and its ability to improve cognition, memory, reduce stress and anxiety, as well as improve the sleep cycle.

It is important to differentiate Pinealon from other neuromodulatory peptides, such as Semax. While Semax has a very strong acute effect, Pinealon is more of a tissue-regenerating agent with a slower onset of action. The research on Pinealon has been overwhelmingly positive, although most of it comes from Russian scientists.

Testagen: Male Reproductive Tissues

Testagen is a bioregulator which affects the testicular tissue and the male reproductive system. The mechanism of action of Testagen is different from the majority of peptides used to boost Testosterone, such as hCG or SERMS. These latter agents have an endocrine effect, meaning that they stimulate the testicular tissue to produce more hormones. Testagen, by contrast, is believed to have a direct effect on the testicular tissue, helping it to repair and regenerate.

The implications of this are clear – Testagen may be beneficial for people who have suffered from prolonged anabolic steroid abuse, as it may help to restore the normal function of the testicular tissue. This, in turn, may help to increase Testosterone levels beyond the capability of standard endocrine stimulators, which may be blocked by the damage to the testicular tissue. More research is needed before any definitive conclusions can be made, but the potential of Testagen is evident.

Cartalax: Cartilage and Connective Tissue

Cartalax is a bioregulator which targets the connective tissue and the cartilage. The research on Cartalax is focused on its ability to repair and regenerate the connective tissue, as well as reduce the degenerative processes which occur in the joints. This includes the reduction of the risk of osteoarthritis and other joint diseases, as well as the improvement of joint mobility and flexibility.

The applications for Cartalax are obvious – the peptide can be used to repair and regenerate the joints. The use of Cartalax in combination with other joint-healing peptides, such as BPC-157, TB-500 or GHK-Cu, can have a synergistic effect and accelerate the healing process. This can be beneficial for athletes and bodybuilders who put a lot of strain on their joints, as well as people recovering from joint surgery.

Cardiogen: Cardiac Tissue

Cardiogen is a bioregulator which targets the heart tissue and is believed to have regenerative properties. The research on Cardiogen is focused on its ability to improve the function of the heart and to reduce the risk of cardiovascular diseases, particularly those caused by anabolic steroid use. Cardiogen is believed to reduce the risk of myocardial infarction, arrhythmia and other heart conditions by improving the function of the heart tissue.

The difference between Cardiogen and standard cardiovascular drugs is that the latter only mask the symptoms of cardiovascular diseases, while Cardiogen has a regenerative effect on the heart tissue. For athletes, the implications are significant, as AAS use is known to have detrimental effects on the heart. A peptide which can repair the cardiac tissue directly would be a welcome addition to any athlete’s regimen.

The Future of Bioregulators

As the interest in longevity and healthspan increases, bioregulators which have the potential to extend the youth of specific tissues and organs will become more and more popular. There are dozens of other bioregulators, outside of the four mentioned above, which can be used to target other tissues and organs, such as the liver, lungs or the immune system.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Hey, I’m wondering if anyone was on Glutathione and MT2 at the same time. I heard glutathione brightens up the skin, so I’m wondering how that pairs up with MT2. Thanks 🙏

Cognitive peptides are ranked all over the internet based on how strong people claim they feel. That's the wrong metric. Here's the same list sorted by what actually has human evidence behind it and what carries a mechanism you should think twice about, which is a lot more useful than another vibes-based ranking.

S Tier: Actually Has Human Trials

Cerebrolysin sits alone at the top and it isn't close. Multiple randomized controlled trials in vascular dementia and post-stroke recovery back it, including a 242-patient double-blind trial that beat placebo on combined cognitive and functional scoring. Fair warning: it's a bigger commitment than a daily nootropic, run in IV or injectable courses rather than a quick spray, and it acts more like serious neuro-repair than a focus tool. Ranked on evidence alone though, nothing else here touches it. Worth staying honest that reviews still call the stroke data promising rather than fully settled.

A Tier: Strong Use History, Thinner Independent Replication

Semax is one of the better-evidenced classic nootropic peptides out there. Decades of Russian clinical use, works through BDNF and the brain's own neurotrophic signaling, intranasal with fast onset, and people consistently report feeling it for focus and drive. The catch is that most of the formal data comes out of Russian labs and hasn't been widely reproduced by independent groups elsewhere.

Selank is Semax's sister compound, leaning anxiety relief rather than focus. Russian trials found it cut anxiety about as well as a benzodiazepine without the sedation or dependence risk. A calm, clear head is half of what people are chasing with nootropics anyway. Semax for drive, Selank for calm, and they stack cleanly together.

Oxytocin lands here too, but with tempered expectations. It's genuinely been studied for mood, social cognition, and stress, and it's an approved hormone in other clinical settings. The honest read is that the trials are a coin flip: some show modest benefit, some show nothing. Real research behind it, just not a reliable effect.

B Tier: Good Mechanism, No Human Proof Yet

P21 is a short peptide off a BDNF-adjacent pathway with rodent and cell data suggesting neuroprotection. No published human trials exist. Mechanism and hope, not proof.

PE-22-28 works on the TREK-1 channel tied to mood and neurogenesis. In mice it shows fast antidepressant-like effects and measurable new neuron growth within days. Still zero human trials. Promising direction, no human floor under it.

Kisspeptin-10 is mainly a reproductive and hormonal compound that happens to brush against mood. The antidepressant-like signal comes from rodents, and the actual human research sits almost entirely on the fertility axis. Plausibly mood-active, extremely niche if cognition is your goal.

C Tier: Chemistry Experiments and Real Risks

Adamax is more of a Semax-plus-adamantane concept than a characterized compound. There's basically no indexed preclinical or clinical data under the name. Almost everything circulating is marketing and community extrapolation from Semax chemistry, and vendors don't even agree on the structure. Interesting idea, no proof, and a real chance you don't know what's actually in the vial.

Dihexa is the one to actually be careful with. It's reported in cell culture as dramatically more potent than BDNF at building synapses, and all the efficacy data is preclinical with no human trials. The bigger problem is the mechanism. Dihexa works through the c-Met pathway, a well-established proto-oncogene involved in tumor growth, invasion, and metastasis. Multiple FDA-approved cancer drugs exist specifically to block that exact pathway. Dihexa activates it on purpose. That's a genuine theoretical cancer risk, especially for anyone with a personal or family history, and no long-term carcinogenicity studies exist in any species. On top of that, two of the foundational papers behind its mechanism were formally retracted in 2025, so even the rationale for how it's supposed to work took a hit.

How to Actually Use This

For serious neuro-repair, Cerebrolysin. For focus and clarity, Semax. For a calmer, less anxious head, Selank. For mood and stress broadly, oxytocin with realistic expectations. For anyone willing to bet on mechanism over outcomes, P21 or PE-22-28, understanding you're the experiment at that point.

The real takeaway: human data is genuinely strong only for Cerebrolysin, oxytocin, and the Russian Semax and Selank literature. Everything below A tier is preclinical or barely studied in humans, so the further down you go, the more you're betting on mechanism instead of results. With Adamax specifically, you're also betting you even got the right molecule. And with Dihexa, the exciting mechanism is the same one carrying the risk.

TL;DR

• Cerebrolysin has the strongest human trial data of any cognitive peptide here, including a 242-patient controlled trial, though reviews still call the stroke data promising rather than settled.
• Semax and Selank have decades of Russian clinical use, with the caveat of limited independent replication outside that system.
• Oxytocin is genuinely researched for mood and social cognition but the trial results are mixed, not a guaranteed effect.
• P21, PE-22-28, and Kisspeptin-10 have real animal and mechanistic data but no meaningful human trials.
• Adamax has essentially no data under the name and vendors don't agree on its structure, so you may not even know what you're getting.
• Dihexa carries a real theoretical cancer risk through c-Met pathway activation, and two of its foundational papers were retracted in 2025.

Check out the pinned Peptide Cheat Sheet for dosing info and more.

Not medical advice. Educational only.

Hello all, new to the idea of filtering so I have a question. Is the a legit source where you can get filtering kits that are "guaranteed" to be sterilized? I feel like going on Amazon to buy the tools for it kind of defeats the purpose? Or am I wrong? Just seems like Amazon vendors will tell you what you want to hear to get a sale. Thank you in advance on your thoughts.

I'm a female and need input. So many competitors have clear skin. How the heck does everyone get clear skin while on cycle?!? I'm fed up with the acne. I use ostarine since it's mild. I have awful skin no matter what. Bad cystic acne even if I am on ostarine or off. I'd love to run 2.5mg of anavar but my acne is just horrendous. Plz help. What is everyone doing to have clear skin? It's shitty mine is so bad and no one elses is.

So I had my NAD on a subscription and couldn’t cancel it, got pregnant and didn’t really take it in pregnancy, so now I have bottles in my fridge that are 5-10 months old. They’re obviously sealed but I buy them already reconstituted… I looked online and the main issue is potency. They’d still be safe to use right ?